Pyridinyl-quinolone compounds, their preparation and use
    2.
    发明授权
    Pyridinyl-quinolone compounds, their preparation and use 失效
    吡啶基 - 喹诺酮化合物,其制备和用途

    公开(公告)号:US5075319A

    公开(公告)日:1991-12-24

    申请号:US405993

    申请日:1989-09-13

    摘要: Fluorinated 1-cyclopropyl-7-(substituted-pyridinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids of the formula ##STR1## wherein R is hydrogen, R' and R" are hydrogen or fluoro, or other groups and Z is 3- or 4-pyridinyl substituted by alkyl groups or substituted alkyl groups, are superior antibacterial agents. They are prepared via a coupling reaction between the corresponding esters (R=alkyl) having a halo group in the 7-position and a substituted (trialkylstannyl)pyridine.

    摘要翻译: 其中R是氢,R'和R“的氟化1-环丙基-7-(取代的 - 吡啶基)-1,4-二氢-4-氧代-3-喹啉羧酸是氢或氟, 或其它基团,Z为被烷基或取代烷基取代的3-或4-吡啶基,是优异的抗菌剂。 它们通过在7-位具有卤代基团的相应酯(R =烷基)和取代的(三烷基甲锡烷基)吡啶之间的偶联反应制备。

    5-(2-Substituted-4-thiazolyl)-6-alkyl-2(1H)-pyridinones and cardiotonic
use thereof
    4.
    发明授权
    5-(2-Substituted-4-thiazolyl)-6-alkyl-2(1H)-pyridinones and cardiotonic use thereof 失效
    5-(2-取代-4-噻唑基)-6-烷基-2(1H) - 吡啶酮及其强心使用

    公开(公告)号:US4539327A

    公开(公告)日:1985-09-03

    申请号:US571281

    申请日:1984-01-16

    CPC分类号: C07D417/04 C07D213/85

    摘要: 3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

    摘要翻译: 3-Q-4-R2-5-(2-Q'-5-R3-4-噻唑基)-6-R1-2(1H) - 吡啶酮(I),其中R1是具有1-4个碳原子的烷基 ,R2是氢或甲基,R3是氢或具有1-3个碳原子的烷基,Q是氨基,氨基甲酰基,羧基,氰基或氢,Q'是具有1-4个碳原子的烷基,氨基或R4NH,其中R4 是具有1-4个碳原子的烷基或其中Q和Q'中的至少一个是氨基或Q'是R 4 NH的酸加成盐可用作强心剂(其中Q是氨基,氰基或氢)和/ 或作为中间体(I,其中Q为氰基,氨基甲酰基或羧基)。 中间体也显示为1,2-二氢-4-R2-5- [R3CH(Br)CO] -6-R1-2-氧代-3-吡啶甲腈(II),并且还涉及制备I和II的方法 。

    Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones
    5.
    发明授权
    Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones 失效
    强心剂使用4,5-二氢-6-(4-吡啶基)-3(2H) - 哒嗪酮

    公开(公告)号:US4486431A

    公开(公告)日:1984-12-04

    申请号:US245086

    申请日:1981-03-18

    IPC分类号: C07D213/57 A61K31/50

    CPC分类号: C07D213/57

    摘要: 4,5-Dihydro-4-R-6-(4-pyridinyl)-3(2H)-pyridazinone (IA) or pharmaceutically-acceptable acid-addition salt thereof, where R is hydrogen or methyl, is shown as the active component in cardiotonic composition and method for increasing cardiac contractility in a patient requiring such treatment. Also shown is the preparation of IA by reacting a lower-alkyl 2-R-4-(BN)-4-cyano-4-(4-pyridinyl)butanoate with hydrazine, where R is hydrogen or methyl, and BN is 4-morpholinyl, 1-piperidinyl or 1-pyrrolidinyl.

    摘要翻译: 4,5-二氢-4-R-6-(4-吡啶基)-3(2H) - 哒嗪酮(IA)或其药学上可接受的酸加成盐,其中R为氢或甲基,表示为活性成分 用于增加需要这种治疗的患者的心脏收缩力的强心剂组合物和方法。 还示出了通过使低级烷基2-R-4-(BN)-4-氰基-4-(4-吡啶基)丁酸酯与肼的反应制备IA,其中R是氢或甲基,BN是4- 吗啉基,1-哌啶基或1-吡咯烷基。

    5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones,
their cardiotonic use and preparation
    6.
    发明授权
    5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation 失效
    5-(羟基 - 和/或氨基 - 苯基)-6-(低级烷基)-2-(1H) - 吡啶酮,它们的强心使用和制备

    公开(公告)号:US4465686A

    公开(公告)日:1984-08-14

    申请号:US372174

    申请日:1982-04-26

    摘要: Disclosed and claimed is the cardiotonic use of 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (II), where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R" are each hydrogen, amino or hydroxy, at least one of R' or R" being other than hydrogen, or where R' is nitro when R" is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R" is amino. Also disclosed and claimed are 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (I), where R.sub.1, R' and R" are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R" is amino. Also shown and claimed is the process which comprises reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-(3-R'-4-R"-phenyl)-6-R-nicotinonitrile, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R" is hydroxy, methoxy or hydrogen, preferably at least one of R' and R" being methoxy, or where R' is nitro and R" is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinone.

    摘要翻译: 公开并要求保护的是强力使用1-R1-5-(3-R'-4-R“ - 苯基)-6-R-2(1H) - 吡啶酮(II),其中R 1是氢, 烷基或低级羟烷基,R为低级烷基或氢,R'和R“各自为氢,氨基或羟基,R'或R”中的至少一个为氢,或其中R'为 当R“为羟基时为硝基,或其药学上可接受的酸加成盐,其中R'和R”中的至少一个为氨基。 还公开和要求保护的是1-R1-5-(3-R'-4-R“ - 苯基)-6-R-2(1H) - 吡啶酮(I),其中R 1,R'和R” R是R'和R“中的至少一个是氨基的低级烷基和酸加成盐。 还显示和要求保护的方法包括使1-R1-1,2-二氢-2-氧代-5-(3-R'-4-R“ - 苯基)-6-R-烟腈反应,其中R 1和 R如上定义为II,R'是氢,羟基,甲氧基或氨基,R“是羟基,甲氧基或氢,优选R'和R”中的至少一个是甲氧基,或其中R'是硝基, R“是氢或甲氧基,优选甲氧基,与85%磷酸反应以产生1-R1-5-(3-R'-4-R” - 苯基)-6-R-2(1H) - 吡啶酮。

    1,2-Dihydro-6-[2-(dimethylamino)ethenyl]-2-oxo-5-(pyridinyl)
nicotinonitriles
    9.
    发明授权
    1,2-Dihydro-6-[2-(dimethylamino)ethenyl]-2-oxo-5-(pyridinyl) nicotinonitriles 失效
    1,2-二氢-6- [2-(二甲基氨基)乙烯基] -2-氧代-5-(吡啶基)烟腈

    公开(公告)号:US4363911A

    公开(公告)日:1982-12-14

    申请号:US298935

    申请日:1981-09-03

    IPC分类号: C07D213/85 C07D401/04

    CPC分类号: C07D213/85

    摘要: 1-R.sub.1 -1,2-dihydro-6-[2-(dimethylamino)ethenyl]-2-oxo-5-PY-nicotinonitriles, where R.sub.1 is hydrogen or methyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically acceptable acid-addition salts thereof are useful as cardiotonic agents. Said compounds are prepared by reacting 1,2-dihydro-6-methyl-2-oxo-5-PY-nicotinonitrile with dimethylformamide dimethylacetal. Shown is the cardiotonic use of said compounds or pharmaceutically acceptable acid-addition salts thereof.

    摘要翻译: 1-R1-1,2-二氢-6- [2-(二甲基氨基)乙烯基] -2-氧代-5-PY-烟酰胺,其中R1是氢或甲基,PY是4-或3-吡啶基或4 - 或具有一个或两个低级烷基取代基的3-吡啶基或其药学上可接受的酸加成盐可用作强心剂。 所述化合物通过1,2-二氢-6-甲基-2-氧代-5-PY-烟腈与二甲基甲酰胺二甲缩醛反应制备。 所示为所述化合物或其药学上可接受的酸加成盐的强力使用。

    5-(Py-Y)-1H-benzimidazol-2-ols and 5-(Py-Y-)-1H-benzimidazole-2-thiols
    10.
    发明授权
    5-(Py-Y)-1H-benzimidazol-2-ols and 5-(Py-Y-)-1H-benzimidazole-2-thiols 失效
    5-(Py-Y)-1H-苯并咪唑-2-醇和5-(Py-Y - ) - 1H-苯并咪唑-2-硫醇

    公开(公告)号:US4335132A

    公开(公告)日:1982-06-15

    申请号:US220977

    申请日:1980-12-29

    CPC分类号: C07D213/40 C07D213/38

    摘要: 5-(Py-Y)-1H-benzimidazol-2-ol or 5-(Py-Y)-1H-benzimidazole-2-thiol or lower-alkyl ethers or thioethers thereof or pharmaceutically-acceptable acid-addition salts thereof, useful as cardiotonics, are prepared by reacting 4-(Py-Y)-1,2-benzenediamine with urear or carbonyldiimidazole to produce 5-(Py-Y)-1H-benzimidazol-2-ol or with thiourea, an alkali metal lower-alkyl xanthate or thiocarbonyldiimidazole to produce 5-(Py-Y)-1H-benzimidazole-2-thiol and by reacting 5-(Py-Y)-1H-benzimidazole-2-thiol with a lower-alkylating agent to produce 2-(lower-alkylthio)-5-(Py-Y)-1H-benzimidazole. 2-(Lower-alkoxy)-5-(Py-Y)-1H-benzimidazole is prepared by reacting 4-(Py-Y)-1,2-benzenediamine with tetra-(lower-alkoxy)methane.

    摘要翻译: 5-(Py-Y)-1H-苯并咪唑-2-醇或5-(Py-Y)-1H-苯并咪唑-2-硫醇或其低级烷基醚或硫醚或其药学上可接受的酸加成盐,有用 作为强心剂,通过4-(Py-Y)-1,2-苯二胺与脲或羰基二咪唑反应制备5-(Py-Y)-1H-苯并咪唑-2-醇或与硫脲反应, 烷基黄原酸酯或硫代羰基二咪唑,得到5-(Py-Y)-1H-苯并咪唑-2-硫醇,并通过使5-(Py-Y)-1H-苯并咪唑-2-硫醇与低级烷基化剂反应生成2-( 低级烷硫基)-5-(Py-Y)-1H-苯并咪唑。 4-(Py-Y)-1,2-苯二胺与四 - (低级烷氧基)甲烷反应制备2-(低级烷氧基)-5-(Py-Y)-1H-苯并咪唑。